Viomycin
From Wikipedia, the free encyclopedia
 |
This article does not cite any references or sources. (November 2006) Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. |
 |
|
|
Viomycin
|
|
| Systematic (IUPAC) name | |
| (3S)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-3-[(4R,6S)-
2-amino-6-hydroxy-3,4,5,6-tetrahydropyrimidin-4-yl]-6- [(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14- pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]hexanamide |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C25H43N13O10 |
| Mol. mass | 685.691 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Viomycin sulfate (Viocin) is an polypeptide antibiotic used in the treatment of tuberculosis. It is produced by the actinomycete Streptomyces puniceus, that binds to RNA and inhibits prokaryotic protein synthesis and certain forms of RNA splicing.
[edit] Administration
Intramuscular injection.
 |
This antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
